Posts
Cancer is a disease caused when cells divide
abnormally and uncontrollably and spread into surrounding tissues, which results
in formation of a mass called tumor. Head and neck
cancer refers to various malignant tumors that develop in or around the mouth,
sinuses, nose, larynx, and throat. Moreover,
head and neck cancer begin in squamous cells that line moist surfaces such as
those inside the throat, nose, and mouth. Infection with human papillomavirus
(HPV), excessive alcohol consumption, and chewing tobacco increases the risk of
head and neck cancer. Other factors such as hereditary causes, Epstein barr
virus infection, radiation exposure, occupational exposure, oral health, salted
or preserved foods, excessive consumption of paan also increases the risk of
head and neck cancer.
Factors such as rise in government initiatives,
surge in research and development activities, rise in health care
infrastructure, and increase in the patient population are expected to propel
the head and neck
cancer market. Worldwide, head and neck
cancer is the sixth-most common cancer, with around 630,000 people diagnosed every
year, resulting in more than 350,000 deaths, according to the National Center
for Biotechnology Information. Moreover, tens of millions of individuals are
diagnosed with cancer each year and more than half of the patients
eventually die from it. Moreover, cancer ranks the second most common
cause of death in many countries, following cardiovascular diseases.
Around 75% of head and neck cancers are
associated with tobacco use. However, in last ten years, the survival rate of
head and neck cancer has dropped to 50% from 80%, as currently available
treatment options primarily treat the symptoms. Furthermore, the introduction
of antibody drug conjugates, monoclonal antibodies, and targeted molecular
therapy such as gene therapy creates major growth avenues for the market. Increasing
incidence of head and neck cancer is also expected to drive the growth of the
market. For instance, around 3 to 5% of the population worldwide suffers from
head and neck cancer, according to the World Health Organization.
In terms of geography, the head and neck cancer
market is divided into six regions, such as North America, South America, Asia
Pacific, Europe, the Middle East, and Africa. Growing geriatric population,
increasing number of initiatives, and increase in product approvals are
creating favorable environment for the head and neck cancer market growth. For
instance, in June 2019, Merck & Co. received the United States Food and
Drug Administration approval for Pembrolizumab for the treatment of people with
metastatic or recurrent head and neck squamous cell carcinoma.
No comments:
Post a Comment